An enervated US and withering haemophilia led to a weak second quarter for Novo Nordisk. The local currency revenue growth of 2% was further eroded by currency headwinds of 6%, while operating growth of 2% culminated in a decline of 9%. While the guidance for the year was maintained, the company is in the middle of pioneering new frontiers, thereby cementing its leadership in the GLP-1 space, but the insulin space gets more and more arid.
10 Aug 2018
The puny quarter
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
The puny quarter
Novo Nordisk A/S Class B (NNO2:WBO) | 0 0 2.2% | Mkt Cap: 611,927m
- Published:
10 Aug 2018 -
Author:
Kamla Singh -
Pages:
3
An enervated US and withering haemophilia led to a weak second quarter for Novo Nordisk. The local currency revenue growth of 2% was further eroded by currency headwinds of 6%, while operating growth of 2% culminated in a decline of 9%. While the guidance for the year was maintained, the company is in the middle of pioneering new frontiers, thereby cementing its leadership in the GLP-1 space, but the insulin space gets more and more arid.